Shreya Agarwal: We Describe Patients With PLG Mutations Who Experienced Recurrent TMA
Shreya Agarwal, Assistant Professor of Pediatric Hematology at UCSF Benioff Children’s Hospitals, reposted from RPTH Journal on LinkedIn:
”Grateful to RPTH for highlighting our recent study on Plasminogen (PLG) mutation- associated thrombotic microangiopathy (TMA).
In this work, we describe patients with PLG mutations who experienced recurrent TMA despite complement blockade therapy, and raises suspicion if there is an alternate disease pathway worth exploring.
We are now hoping to assess the feasibility of a multicenter study to better understand PLG mutations-associated TMA.
If you’ve cared for patients with plasminogen mutations and TMA, we’d be grateful if you could take a few minutes to complete our short survey.
Thank you to my amazing coauthors Nicola Pozzi, Senthil Sukumar, Camila Masias MD, Anuja Java and Spero Cataland for their collaboration on this project!”
Quoting RPTH Journal‘s post:
”Not all thrombotic microangiopathies (TMAs) behave the same, and they don’t all respond to complement blockade.
In a new study, Shreya Agarwal, MD and team describe a subset of patients with plasminogen (PLG) mutations who experienced recurrent TMA despite standard therapy.
Their response to anticoagulation hints at an alternative disease pathway worth exploring.
Coauthors: Nicola Pozzi; Senthil Sukumar, Camila Masias MD, Spero Cataland’‘
Read the full article in RPTH.
Article: Plasminogen mutation–associated thrombotic microangiopathy and role of anticoagulation: a single institution case series
Authors: Shreya Agarwal, Nicola Pozzi, Senthil Sukumar, Camila Masias, Anuja Java, Spero Cataland
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Sep 18, 2026, 17:32Hassan Kawtharany: New Ferritin Cutoffs for the Diagnosis of Iron Deficiency With or Without Anemia
-
Sep 18, 2026, 17:20Abhishek G P: GAVE as an Important Cause of Chronic Gastrointestinal Blood Loss
-
Sep 18, 2026, 17:08Irem Karaman Sebin: ASH 2026 Changes a Key Concept in Iron Deficiency
-
Sep 18, 2026, 16:51Adarsh Krishnan Sundara Rajan: Is VTE the Most Underdiagnosed Critical Threat in Modern Healthcare?
-
Sep 18, 2026, 16:19CRISPR and Hemophilia: The Next Frontier of In Vivo Gene Editing
-
Sep 18, 2026, 16:13Christian Irsara: PF4 Immunothrombosis Following Natural Adenovirus Infection
-
Sep 18, 2026, 16:10Leo Nicolai։ The Spleen Emerges as a Key Regulator of Thromboinflammation
-
Sep 18, 2026, 16:05Targeting Factor XI to Reduce Thrombosis Without Compromising Hemostasis – ISTH
-
Sep 18, 2026, 15:54Swapnil Pawar: Why Aren’t We Using Cryopreserved Platelets Everywhere Yet?